{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:37:09Z","timestamp":1793763429148,"version":"4.6.1"},"reference-count":26,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T00:00:00Z","timestamp":1712188800000},"content-version":"unspecified","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014848","name":"Arnold Ventures","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014848","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["bmjmed"],"accepted":{"date-parts":[[2024,2,24]]},"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate National Comprehensive Cancer Network (NCCN) guideline recommendations for oncology drug treatments that have been granted accelerated approval, and to determine whether recommendations are updated based on the results of confirmatory trials after approval and based on status updates from the US Food and Drug Administration (FDA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Cross sectional study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>US FDA and NCCN guidelines.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Population<\/jats:title>\n                  <jats:p>Oncology therapeutic indications (ie, specific oncological conditions for which the drug is recommended) that have been granted accelerated approval in 2009-18.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main outcome measures<\/jats:title>\n                  <jats:p>NCCN guideline reporting of accelerated approval status and postapproval confirmatory trials, and guideline recommendation alignment with postapproval confirmatory trial results and FDA status updates.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>39 oncology drug treatments were granted accelerated approval for 62 oncological indications. Although all indications were recommended in NCCN guidelines, accelerated approval status was reported for 10 (16%) indications. At least one postapproval confirmatory trial was identified for all 62 indications, 33 (53%) of which confirmed benefit; among these indications, NCCN guidelines maintained the previous recommendation or strengthened the category of evidence for 27 (82%). Postapproval confirmatory trials failed to confirm benefit for 12 (19%) indications; among these indications, NCCN guidelines removed the previous recommendation or weakened the category of evidence for five (42%). NCCN guidelines reflected the FDA's decision to convert 30 (83%) of 36 indications from accelerated to traditional approval, of which 20 (67%) had guideline updates before the FDA's conversion decision. NCCN guidelines reflected the FDA's decision to withdraw seven (58%) of 12 indications from the market, of which four (57%) had guidelines updates before the FDA's withdrawal decision.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>NCCN guidelines always recommend drug treatments that have been granted accelerated approval for oncological indications, but do not provide information about their accelerated approval status, including surrogate endpoint use and status of postapproval confirmatory trials. NCCN guidelines consistently provide information on postapproval trial results confirming clinical benefit, but not on postapproval trials failing to confirm clinical benefit. NCCN guidelines more frequently update recommendation for indications converted to traditional approval than for those approvals that were withdrawn.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjmed-2023-000802","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T12:05:11Z","timestamp":1712318711000},"page":"e000802","source":"Crossref","is-referenced-by-count":10,"title":["Characterization of accelerated approval status, trial endpoints and results, and recommendations in guidelines for oncology drug treatments from the National Comprehensive Cancer Network: cross sectional study"],"prefix":"10.1136","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9347-494X","authenticated-orcid":false,"given":"Maryam","family":"Mooghali","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA"},{"name":"Yale Collaboration for Regulatory Rigor, Integrity, and Transparency, Yale School of Medicine, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3639-3515","authenticated-orcid":false,"given":"Aaron P","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3527-4277","authenticated-orcid":false,"given":"Joshua J","family":"Skydel","sequence":"additional","affiliation":[{"name":"Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9218-3320","authenticated-orcid":false,"given":"Joseph S","family":"Ross","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA"},{"name":"Yale Collaboration for Regulatory Rigor, Integrity, and Transparency, Yale School of Medicine, New Haven, CT, USA"},{"name":"Department of Health Policy and Management, Yale School of Public Health; and Center for Outcomes Research and Evaluation, Yale New Haven Health System, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D","family":"Wallach","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Rollins School of Public Health, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3845-3606","authenticated-orcid":false,"given":"Reshma","family":"Ramachandran","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA"},{"name":"Yale Collaboration for Regulatory Rigor, Integrity, and Transparency, Yale School of Medicine, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,4,5]]},"reference":[{"key":"2025080501045903000_3.1.e000802.1","unstructured":"U.S . Accelerated approval: FDA. 2018. Available: https:\/\/www.fda.gov\/patients\/fast-track-breakthrough-therapy-accelerated-approval-priorityreview\/accelerated-approval [Accessed 23 Jun 2023]."},{"key":"2025080501045903000_3.1.e000802.2","unstructured":"U.S . Guidance for industry: expedited programs for serious conditions \u2013 drugs and Biologics.: FDA. 2014. Available: https:\/\/www.fda.gov\/media\/86377\/download [Accessed 23 Jun 2023]."},{"key":"2025080501045903000_3.1.e000802.3","unstructured":"U.S . Project confirm: promoting the transparency of accelerated approval for oncology indications. 2023. Available: https:\/\/www.fda.gov\/about-fda\/oncology-center-excellence\/project-confirm"},{"key":"2025080501045903000_3.1.e000802.4","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31957"},{"key":"2025080501045903000_3.1.e000802.5","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100332","article-title":"Evaluating the evidence behind the Surrogate measures included in the FDA\u2019s table of Surrogate endpoints as supporting approval of cancer drugs","volume":"21","author":"Gyawali","year":"2020","journal-title":"EClinicalMedicine"},{"key":"2025080501045903000_3.1.e000802.6","doi-asserted-by":"crossref","first-page":"100364","DOI":"10.1016\/j.jcpo.2022.100364","article-title":"FDA validation of Surrogate endpoints in oncology: 2005\u20132022","volume":"34","author":"Walia","year":"2022","journal-title":"J Cancer Policy"},{"key":"2025080501045903000_3.1.e000802.7","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s11606-018-4779-x","article-title":"Timeliness of Postmarket studies for new pharmaceuticals approved between 2009 and 2012: a cross-sectional analysis","volume":"34","author":"Wallach","year":"2019","journal-title":"J Gen Intern Med"},{"key":"2025080501045903000_3.1.e000802.8","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.33601","article-title":"Comparison of duration of Postapproval vs pivotal trials for therapeutic agents granted US food and Drug Administration accelerated approval, 2009-2018","volume":"4","author":"Wallach","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2025080501045903000_3.1.e000802.9","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jamaoncol.2017.5618","article-title":"A 25-year experience of US food and Drug Administration accelerated approval of malignant hematology and oncology drugs and Biologics: A review","volume":"4","author":"Beaver","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025080501045903000_3.1.e000802.10","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamainternmed.2019.0462","article-title":"Assessment of the clinical benefit of cancer drugs receiving accelerated approval","volume":"179","author":"Gyawali","year":"2019","journal-title":"JAMA Intern Med"},{"key":"2025080501045903000_3.1.e000802.11","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/phar.2789","article-title":"Accelerated approval drug labels often lack information for clinical decision-making","volume":"43","author":"Ballreich","year":"2023","journal-title":"Pharmacotherapy"},{"key":"2025080501045903000_3.1.e000802.12","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1136\/bmj.n2059","article-title":"Should regulatory authorities approve drugs based on Surrogate Endpoints?BMJ 2021;374:N2059","volume":"374","author":"Lenzer","year":"2021","journal-title":"BMJ"},{"key":"2025080501045903000_3.1.e000802.13","unstructured":"The National Comprehensive Cancer Network . About clinical practice guidelines. 2022. Available: https:\/\/www.nccn.org\/guidelines\/guidelines-process\/about-nccn-clinical-practice- guidelines#:~:text=The%20NCCN%20Guidelines%C2%AE%20are,in%20any%20area%20of%20medicine [Accessed 14 Jun 2020]."},{"key":"2025080501045903000_3.1.e000802.14","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1136\/bmj.n1959","article-title":"Regulatory and clinical consequences of negative Confirmatory trials of accelerated approval cancer drugs: retrospective observational study","volume":"374","author":"Gyawali","year":"2021","journal-title":"BMJ"},{"key":"2025080501045903000_3.1.e000802.15","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1001\/jamaoncol.2022.7770","article-title":"Exposure to US cancer drugs with lack of confirmed benefit after US food and Drug Administration accelerated approval","volume":"9","author":"Parikh","year":"2023","journal-title":"JAMA Oncol"},{"key":"2025080501045903000_3.1.e000802.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2014.07.013"},{"key":"2025080501045903000_3.1.e000802.17","unstructured":"U.S . Drugs@FDA: FDA-approved drugs. 2023. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/"},{"key":"2025080501045903000_3.1.e000802.18","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology . ATC\/DDD index. 2023. Available: https:\/\/www.whocc.no\/atc_ddd_index\/"},{"key":"2025080501045903000_3.1.e000802.19","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1177\/17407745211005044","article-title":"US food and Drug Administration utilization of Postmarketing requirements and Postmarketing commitments, 2009-2018","volume":"18","author":"Skydel","year":"2021","journal-title":"Clin Trials"},{"key":"2025080501045903000_3.1.e000802.20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.282034"},{"key":"2025080501045903000_3.1.e000802.21","unstructured":"National Comprehensive Cancer Network. Permission to Cite or Use NCCN Content, . 2023 Available: https:\/\/www.nccn.org\/guidelines\/permission-to-cite-or-use-nccn-content"},{"key":"2025080501045903000_3.1.e000802.22","unstructured":"National Comprehensive Cancer Network . Development and update of guidelines. 2023. Available: https:\/\/www.nccn.org\/guidelines\/guidelines-process\/development-and-update-ofguidelines"},{"key":"2025080501045903000_3.1.e000802.23","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1056\/NEJMp2104846","article-title":"Dangling\u201d accelerated approvals in oncology","volume":"384","author":"Beaver","year":"2021","journal-title":"N Engl J Med"},{"key":"2025080501045903000_3.1.e000802.24","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2010.0048"},{"key":"2025080501045903000_3.1.e000802.25","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2022.1158","article-title":"Spending by the centers for Medicare & Medicaid services before and after confirmation of benefit for drugs granted US food and Drug Administration accelerated approval, 2012 to 2017","volume":"3","author":"Skydel","year":"2022","journal-title":"JAMA Health Forum"},{"key":"2025080501045903000_3.1.e000802.26","doi-asserted-by":"crossref","unstructured":"Schwartz LM , Woloshin S . The drug facts box: improving the communication of prescription drug information. Proc Natl Acad Sci U S A 2013:14069\u201374. doi:10.1073\/pnas.1214646110","DOI":"10.1073\/pnas.1214646110"}],"container-title":["BMJ Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjmed-2023-000802","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T08:05:12Z","timestamp":1754381112000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjmedicine.bmj.com\/lookup\/doi\/10.1136\/bmjmed-2023-000802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,4,5]]},"published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1136\/bmjmed-2023-000802"],"URL":"https:\/\/doi.org\/10.1136\/bmjmed-2023-000802","relation":{},"ISSN":["2754-0413"],"issn-type":[{"value":"2754-0413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]}}}